These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10406696)

  • 1. Modification of molecular events in coronary restenosis using coated stents: The Mayo Clinic Approach.
    Keelan PC; Miyauchi K; Caplice NM; Ashai KH; Schwartz RS
    Semin Interv Cardiol; 1998; 3(3-4):211-5. PubMed ID: 10406696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomimicry, vascular restenosis and coronary stents.
    Schwartz RS; van der Giessen WJ; Holmes DR
    Semin Interv Cardiol; 1998; 3(3-4):151-6. PubMed ID: 10406686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model.
    Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries.
    Johnson TW; Wu YX; Herdeg C; Baumbach A; Newby AC; Karsch KR; Oberhoff M
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):754-9. PubMed ID: 15681295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.
    Blindt R; Vogt F; Astafieva I; Fach C; Hristov M; Krott N; Seitz B; Kapurniotu A; Kwok C; Dewor M; Bosserhoff AK; Bernhagen J; Hanrath P; Hoffmann R; Weber C
    J Am Coll Cardiol; 2006 May; 47(9):1786-95. PubMed ID: 16682302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia.
    Swanson N; Hogrefe K; Javed Q; Malik N; Gershlick AH
    J Invasive Cardiol; 2003 Dec; 15(12):688-92. PubMed ID: 14660819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [State of treatment of coronary artery disease by drug releasing stents].
    Müller R; Büllesfeld L; Gerckens U; Grube E
    Herz; 2002 Sep; 27(6):508-13. PubMed ID: 12378395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization.
    Liuzzo JP; Ambrose JA; Coppola JT
    J Invasive Cardiol; 2005 Sep; 17(9):497-502. PubMed ID: 16145242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model.
    Huang Y; Liu X; Wang L; Verbeken E; Li S; De Scheerder I
    Int J Cardiovasc Intervent; 2003; 5(3):166-71. PubMed ID: 12959735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymer stent coating for prevention of neointimal hyperplasia.
    Billinger M; Buddeberg F; Hubbell JA; Elbert DL; Schaffner T; Mettler D; Windecker S; Meier B; Hess OM
    J Invasive Cardiol; 2006 Sep; 18(9):423-6; discussion 427. PubMed ID: 16954581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventional cardiology--promises and challenges.
    Roguin A; Beyar R
    Isr Med Assoc J; 1999 Oct; 1(2):104-11. PubMed ID: 10731308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stent-based percutaneous coronary interventions in small coronary arteries.
    Roguin A; Grenadier E
    Acute Card Care; 2006; 8(2):70-4. PubMed ID: 16885069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The radioactive stent--any chance of a resurrection?
    Arab A; Bode C; Hehrlein C
    Eur Heart J; 2001 Aug; 22(15):1245-7. PubMed ID: 11465956
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model.
    Huang Y; Salu K; Wang L; Liu X; Li S; Lorenz G; Wnendt S; Verbeken E; Bosmans J; Van de Werf F; De Scheerder I
    J Invasive Cardiol; 2005 Mar; 17(3):142-8. PubMed ID: 15867441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endovascular stent configuration affects intraluminal flow dynamics and in vitro endothelialization.
    Akagawa E; Ookawa K; Ohshima N
    Biorheology; 2004; 41(6):665-80. PubMed ID: 15851843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical restenosis models: challenges and successes.
    Touchard AG; Schwartz RS
    Toxicol Pathol; 2006; 34(1):11-8. PubMed ID: 16507539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.